Golodirsen    (DrugBank: Golodirsen)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
113筋ジストロフィー11

113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
11 / 567 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004625-32-BG
(EUCTR)
03/12/202028/10/2020A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
INN or Proposed INN: CASIMERSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 45 skipping
Product Name: SRP-4053
Product Code: SRP-4053
INN or Proposed INN: GOLODIRSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 53 skipping
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
150Phase 3United States;Czechia;Spain;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Bulgaria;Germany;Sweden
2EUCTR2017-004625-32-SE
(EUCTR)
17/06/202009/08/2018A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
INN or Proposed INN: CASIMERSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 45 skipping
Product Name: SRP-4053
Product Code: SRP-4053
INN or Proposed INN: GOLODIRSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 53 skipping
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
260Phase 3United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany;Sweden
3NCT04179409
(ClinicalTrials.gov)
February 18, 202012/8/2019A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD DuplicationsA 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD DuplicationsDuchenne Muscular DystrophyDrug: Casimersen;Drug: Eteplirsen;Drug: GolodirsenKevin FlaniganSarepta Therapeutics, Inc.Enrolling by invitation6 MonthsN/AMale6Phase 2United States
4EUCTR2017-004625-32-FR
(EUCTR)
05/02/201923/07/2018A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: no
Male: yes
260Phase 3United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany;Sweden
5EUCTR2017-004625-32-BE
(EUCTR)
20/12/201810/09/2018A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: no
Male: yes
150Phase 3United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2017-004625-32-ES
(EUCTR)
07/09/201810/09/2018A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
INN or Proposed INN: CASIMERSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 45 skipping
Product Name: SRP-4053
Product Code: SRP-4053
INN or Proposed INN: GOLODIRSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 53 skipping
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
150Phase 3United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany;Sweden
7NCT03532542
(ClinicalTrials.gov)
August 2, 201810/5/2018An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyLong-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or GolodirsenDuchenne Muscular DystrophyDrug: Casimersen;Drug: GolodirsenSarepta Therapeutics, Inc.NULLEnrolling by invitation7 Years23 YearsMale260Phase 3United States;Belgium;Czechia;Germany;Israel;Italy;Spain;Sweden;United Kingdom
8EUCTR2017-004625-32-GB
(EUCTR)
26/07/201823/01/2019A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
INN or Proposed INN: CASIMERSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 45 skipping
Product Name: SRP-4053
Product Code: SRP-4053
INN or Proposed INN: GOLODIRSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 53 skipping
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
260Phase 3United States;Finland;Spain;Ireland;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany;Sweden
9EUCTR2017-004625-32-CZ
(EUCTR)
09/09/2019A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Sarepta Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: no
Male: yes
260Phase 3United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany;Sweden
10EUCTR2017-004625-32-DE
(EUCTR)
26/07/2018A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
INN or Proposed INN: CASIMERSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 45 skipping
Product Name: SRP-4053
Product Code: SRP-4053
INN or Proposed INN: GOLODIRSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 53 skipping
Sarepta Therapeutics, Inc.NULLNAFemale: no
Male: yes
260Phase 3United States;Czechia;Finland;Spain;Ireland;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Belgium;Poland;Australia;Bulgaria;Germany;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2017-004625-32-PL
(EUCTR)
07/11/2019A long-term extension study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsLong-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
INN or Proposed INN: CASIMERSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 45 skipping
Product Name: SRP-4053
Product Code: SRP-4053
INN or Proposed INN: GOLODIRSEN
Other descriptive name: Phosphorodiamidate morpholino oligomer for exon 53 skipping
Sarepta Therapeutics, Inc.NULLNAFemale: no
Male: yes
260Phase 3United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany;Sweden